{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:31:52Z","timestamp":1794508312917,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Kyverna Therapeutics","id":[{"id":"https:\/\/ror.org\/02jkbkr44","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Kyverna Therapeutics, Else Kr\u00f6ner-Fresenius Foundation","id":[{"id":"https:\/\/ror.org\/02jkbkr44","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41591-026-04603-3","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:03:59Z","timestamp":1787821439000},"page":"3862-3873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2697-9080","authenticated-orcid":false,"given":"Fredrik N.","family":"Albach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-7838","authenticated-orcid":false,"given":"Marie C.","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4531-9889","authenticated-orcid":false,"given":"Marie Luise","family":"H\u00fctter-Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8020-354X","authenticated-orcid":false,"given":"Thanh Hang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-4028","authenticated-orcid":false,"given":"Julia M.","family":"Giezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Torgutalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-7832","authenticated-orcid":false,"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-6759","authenticated-orcid":false,"given":"Thorben","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-2177","authenticated-orcid":false,"given":"Jan","family":"Zernicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Nuesch Germano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-1342","authenticated-orcid":false,"given":"Johan","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-3222","authenticated-orcid":false,"given":"Maria","family":"Dzamukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7897-7116","authenticated-orcid":false,"given":"Simon","family":"Schallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5197-2286","authenticated-orcid":false,"given":"Aimo","family":"Kannt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1366-1628","authenticated-orcid":false,"given":"Michaela","family":"Fehringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Unterwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Beling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpida","family":"Phithak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0814-4995","authenticated-orcid":false,"given":"Manfred","family":"Wuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Movassaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eicke","family":"Latz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-1740","authenticated-orcid":false,"given":"Thomas","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-6947","authenticated-orcid":false,"given":"Antonia","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-5617","authenticated-orcid":false,"given":"Hans Ulrich","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-6414","authenticated-orcid":false,"given":"Rene E. M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-5510","authenticated-orcid":false,"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7820","authenticated-orcid":false,"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-4325","authenticated-orcid":false,"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"4603_CR1","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328\u20132337 (2017).","journal-title":"Lancet"},{"key":"4603_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","volume":"14","author":"HU Scherer","year":"2018","unstructured":"Scherer, H. U., Huizinga, T. W. J., Kr\u00f6nke, G., Schett, G. & Toes, R. E. M. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat. Rev. Rheumatol. 14, 157\u2013169 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4603_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108360","volume":"212","author":"SE Elliott","year":"2020","unstructured":"Elliott, S. E. et al. B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF-\u03b1 production. Clin. Immunol. 212, 108360 (2020).","journal-title":"Clin. Immunol."},{"key":"4603_CR4","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"key":"4603_CR5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","volume":"71","author":"W Stohl","year":"2012","unstructured":"Stohl, W. et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann. Rheum. Dis. 71, 1289\u20131296 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR6","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","volume":"70","author":"PC Taylor","year":"2011","unstructured":"Taylor, P. C. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70, 2119\u20132125 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR7","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S2665-9913(21)00220-4","volume":"3","author":"K Tascilar","year":"2021","unstructured":"Tascilar, K. et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol 3, e767\u2013e777 (2021).","journal-title":"Lancet Rheumatol"},{"key":"4603_CR8","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2018-214898","volume":"78","author":"S Pollastro","year":"2019","unstructured":"Pollastro, S. et al. Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Ann. Rheum. Dis. 78, 1339\u20131345 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheumatic Dis. 84, 2065\u20132074 (2025).","journal-title":"Ann. Rheumatic Dis."},{"key":"4603_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103320","volume":"149","author":"S Neppelenbroek","year":"2024","unstructured":"Neppelenbroek, S. et al. Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis. J. Autoimmun. 149, 103320 (2024).","journal-title":"J. Autoimmun."},{"key":"4603_CR11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/annrheumdis-2018-214868","volume":"78","author":"DM Boeters","year":"2019","unstructured":"Boeters, D. M., Burgers, L. E., Toes, R. E. M. & van der Helm-van Mil, A. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status. Ann. Rheumatic Dis. 78, 1497\u20131504 (2019).","journal-title":"Ann. Rheumatic Dis."},{"key":"4603_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","volume":"25","author":"J Avouac","year":"2026","unstructured":"Avouac, J. et al. Roads and detours for CAR T cell therapy in autoimmune diseases. Nat. Rev. Drug Discov. 25, 290\u2013309 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4603_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41591-026-04430-6","volume":"32","author":"G Schett","year":"2026","unstructured":"Schett, G. & Xu, H. Resetting autoimmune disease with CAR cell therapies. Nat. Med. 32, 2007\u20132016 (2026).","journal-title":"Nat. Med."},{"key":"4603_CR14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4603_CR15","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","volume":"32","author":"F M\u00fcller","year":"2026","unstructured":"M\u00fcller, F. et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial. Nat. Med. 32, 1142\u20131151 (2026).","journal-title":"Nat. Med."},{"key":"4603_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"4603_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41591-025-04191-8","volume":"32","author":"M Becilli","year":"2026","unstructured":"Becilli, M. et al. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases. Nat. Med. 32, 1105\u20131117 (2026).","journal-title":"Nat. Med."},{"key":"4603_CR18","doi-asserted-by":"crossref","first-page":"e004727","DOI":"10.1136\/rmdopen-2024-004727","volume":"10","author":"D Szabo","year":"2024","unstructured":"Szabo, D. et al. Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10, e004727 (2024).","journal-title":"RMD Open"},{"key":"4603_CR19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A. et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann. Rheum. Dis. 83, 1597\u20131598 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","volume":"34","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res. 34, 220\u2013223 (2025).","journal-title":"Cell Res."},{"key":"4603_CR21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","volume":"84","author":"M Lidar","year":"2025","unstructured":"Lidar, M. et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann. Rheum. Dis. 84, 370\u2013372 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR22","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1093\/rheumatology\/keaf077","volume":"64","author":"FN Albach","year":"2025","unstructured":"Albach, F. N. et al. Targeting autoimmunity with CD19-CAR T cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology 64, 4075\u20134077 (2025).","journal-title":"Rheumatology"},{"key":"4603_CR23","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.ero.2025.08.008","volume":"2","author":"RN Albach","year":"2025","unstructured":"Albach, R. N. et al. Rapid and profound treatment response of difficult-to-treat rheumatoid arthritis to CD19 CAR T-cell therapy. EULAR Rheumatol. Open 2, 100053 (2025).","journal-title":"EULAR Rheumatol. Open"},{"key":"4603_CR24","doi-asserted-by":"crossref","first-page":"e70139","DOI":"10.1002\/acr2.70139","volume":"7","author":"R Caricchio","year":"2025","unstructured":"Caricchio, R. et al. A guide for initiating and managing chimeric antigen receptor T cell therapy clinical trials in autoimmune rheumatic diseases. ACR Open Rheumatol. 7, e70139 (2025).","journal-title":"ACR Open Rheumatol."},{"key":"4603_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco, R. et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine 69, 102476 (2024).","journal-title":"eClinicalMedicine"},{"key":"4603_CR26","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"4603_CR27","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959\u20133964 (2008).","journal-title":"Blood"},{"key":"4603_CR28","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","volume":"26","author":"S Alivernini","year":"2020","unstructured":"Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295\u20131306 (2020).","journal-title":"Nat. Med."},{"key":"4603_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4603_CR30","doi-asserted-by":"crossref","first-page":"eadj6251","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu, L., Xie, M., Yang, B., Zhao, W. B. & Cao, J. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci. Adv. 10, eadj6251 (2024).","journal-title":"Sci. Adv."},{"key":"4603_CR31","doi-asserted-by":"crossref","first-page":"e005079","DOI":"10.1136\/rmdopen-2024-005079","volume":"11","author":"A Manzo","year":"2025","unstructured":"Manzo, A. et al. Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study. RMD Open 11, e005079 (2025).","journal-title":"RMD Open"},{"key":"4603_CR32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","volume":"49","author":"M B\u00e9c\u00e8de","year":"2019","unstructured":"B\u00e9c\u00e8de, M. et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin. Arthritis Rheum. 49, 211\u2013217 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"4603_CR33","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146\u20132154 (2003).","journal-title":"Arthritis Rheum."},{"key":"4603_CR34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2016.09.011","volume":"46","author":"C Wunderlich","year":"2017","unstructured":"Wunderlich, C., Oliviera, I., Figueiredo, C. P., Rech, J. & Schett, G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-a longitudinal analysis. Semin. Arthritis Rheum. 46, 709\u2013714 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"4603_CR35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe, T. H. et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology 58, 1075\u20131085 (2019).","journal-title":"Rheumatology"},{"key":"4603_CR36","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar2789","volume":"11","author":"M Rehnberg","year":"2009","unstructured":"Rehnberg, M., Amu, S., Tarkowski, A., Bokarewa, M. I. & Brisslert, M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 11, R123 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"4603_CR37","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci, L. et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat. Med. 30, 1593\u20131601 (2024).","journal-title":"Nat. Med."},{"key":"4603_CR38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","volume":"43","author":"JL Halliley","year":"2015","unstructured":"Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow. Immunity 43, 132\u2013145 (2015).","journal-title":"Immunity"},{"key":"4603_CR39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","volume":"393","author":"L Bucci","year":"2025","unstructured":"Bucci, L. et al. BCMA T-cell engager therapy in patients with refractory autoimmune disease. N. Engl. J. Med. 393, 1544\u20131547 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4603_CR40","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","volume":"32","author":"C D\u00fcsing","year":"2026","unstructured":"D\u00fcsing, C. et al. Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat. Med. 32, 1530\u20131542 (2026).","journal-title":"Nat. Med."},{"key":"4603_CR41","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng, J. et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. 31, 3725\u20133736 (2025).","journal-title":"Nat. Med."},{"key":"4603_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35264-8","volume":"14","author":"JS Moon","year":"2023","unstructured":"Moon, J. S. et al. Cytotoxic CD8. Nat. Commun. 14, 319 (2023).","journal-title":"Nat. Commun."},{"key":"4603_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","volume":"570","author":"AP Croft","year":"2019","unstructured":"Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246\u2013251 (2019).","journal-title":"Nature"},{"key":"4603_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","volume":"16","author":"G Nygaard","year":"2020","unstructured":"Nygaard, G. & Firestein, G. S. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat. Rev. Rheumatol. 16, 316\u2013333 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4603_CR45","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2665-9913(23)00094-2","volume":"5","author":"PC Taylor","year":"2023","unstructured":"Taylor, P. C. Pain in the joints and beyond; the challenge of rheumatoid arthritis. Lancet Rheumatol. 5, e351\u2013e360 (2023).","journal-title":"Lancet Rheumatol."},{"key":"4603_CR46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keae544","volume":"64","author":"ZLM Hofman","year":"2025","unstructured":"Hofman, Z. L. M. et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? Rheumatology 64, 65\u201373 (2025).","journal-title":"Rheumatology"},{"key":"4603_CR47","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum."},{"key":"4603_CR48","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270\u2013280 (2020).","journal-title":"Nat. Med."},{"key":"4603_CR49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcyt.2024.09.008","volume":"27","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos, D. et al. Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders. Cytotherapy 27, 236\u2013246 (2025).","journal-title":"Cytotherapy"},{"key":"4603_CR50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4603_CR51","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells, G. et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68, 954\u2013960 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727\u2013735 (1995).","journal-title":"Arthritis Rheum."},{"key":"4603_CR53","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella, D. et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J. Rheumatol. 32, 811\u2013819 (2005).","journal-title":"J. Rheumatol."},{"key":"4603_CR54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ard.2008.102137","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror, R., Tubach, F., Baron, G., Guillemin, F. & Ravaud, P. Measure of function in rheumatoid arthritis: individualised or classical scales? Ann. Rheum. Dis. 69, 97\u2013101 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"4603_CR55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham, F. et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin. Arthritis Rheum. 44, 123\u2013130 (2014).","journal-title":"Semin. Arthritis Rheum."},{"key":"4603_CR56","doi-asserted-by":"crossref","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","volume":"3","author":"MA D\u2019Agostino","year":"2017","unstructured":"D\u2019Agostino, M. A. et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce. RMD Open 3, e000428 (2017).","journal-title":"RMD Open"},{"key":"4603_CR57","doi-asserted-by":"crossref","first-page":"e172006","DOI":"10.1172\/jci.insight.172006","volume":"8","author":"S Reijm","year":"2023","unstructured":"Reijm, S. et al. Autoreactive B cells in rheumatoid arthritis include mainly activated CXCR3+ memory B cells and plasmablasts. JCI Insight 8, e172006 (2023).","journal-title":"JCI Insight"},{"key":"4603_CR58","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cyto.a.23904","volume":"97","author":"S Van Gassen","year":"2020","unstructured":"Van Gassen, S., Gaudilliere, B., Angst, M. S., Saeys, Y. & Aghaeepour, N. CytoNorm: a normalization algorithm for cytometry data. Cytometry A 97, 268\u2013278 (2020).","journal-title":"Cytometry A"},{"key":"4603_CR59","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41596-024-00963-7","volume":"19","author":"D Falck","year":"2024","unstructured":"Falck, D. & Wuhrer, M. GlYcoLISA: antigen-specific and subclass-specific IgG Fc glycosylation analysis based on an immunosorbent assay with an LC-MS readout. Nat. Protoc. 19, 1887\u20131909 (2024).","journal-title":"Nat. Protoc."},{"key":"4603_CR60","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1021\/acs.jproteome.4c00538","volume":"23","author":"S Gijze","year":"2024","unstructured":"Gijze, S. et al. Simultaneous protein quantitation and glycosylation profiling of antigen-specific immunoglobulin G1 in large clinical studies. J. Proteome Res. 23, 5600\u20135605 (2024).","journal-title":"J. Proteome Res"},{"key":"4603_CR61","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41591-021-01409-3","volume":"27","author":"T Vogl","year":"2021","unstructured":"Vogl, T. et al. Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota. Nat. Med. 27, 1442\u20131450 (2021).","journal-title":"Nat. Med."},{"key":"4603_CR62","doi-asserted-by":"crossref","first-page":"aaa0698","DOI":"10.1126\/science.aaa0698","volume":"348","author":"GJ Xu","year":"2015","unstructured":"Xu, G. J. et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 348, aaa0698 (2015).","journal-title":"Science"},{"key":"4603_CR63","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1093\/nar\/gkr424","volume":"39","author":"M Lundberg","year":"2011","unstructured":"Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 39, e102 (2011).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04603-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:18:21Z","timestamp":1792102701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04603-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4603"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04603-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T. is a member of the executive committee of ASAS and a member of GRAPPA and has received research support and consultant fees from AbbVie, UCB and Jannsen. I.M. has received speaker\u2019s honoraria from AbbVie, Bristol Myers Squibb, Lilly, Novartis Pharma and CSL Vifor, consultant fees from AbbVie and travel support from AbbVie and Novartis Pharma. T.W. has received speaker\u2019s honoraria from Johnson & Johnson, AbbVie and Novartis and travel grants from AbbVie, UCB Pharma and Johnson & Johnson, and is on the advisory board of Johnson & Johnson, UCB Pharma and Alfasigma. E.P. has received speaker\u2019s honoraria from Sobi and DVE. O.P. has received honoraria or travel support from Alexion, Gilead, Jazz, MSD, Neovii, Novartis, Pfizer and Therakos. He has received research support from Incyte, Gilead and Priothera and is a member of advisory boards to Apogepha, Alexion, Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Orca Bio, Priothera, Sanofi, Shionogi and SOBI. T.A. has received funding from Johnson & Johnson and honoraria from AbbVie, Amgen, AstraZeneca, GSK and ZenasBiopharma. T.D. has received financial support (paid to the university) for clinical studies from BMS, Novartis and Roche and honoraria for scientific advice or independent data monitoring committee boards from Amgen, Abalzeta, BMS, GSK, Novartis and Roche\/GNE. E.L. is scientific cofounder of IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics and Beren Therapeutics. G.S. has received speaker\u2019s honoraria from BMS, Cabaletta, Jannsen, Novartis and UCB. H.U.S. is a consultant for GSK, on the advisory board of AlfaSigma and received speaker\u2019s honoraria (paid to Leiden University Medical Center) from Miltenyi and Takeda. L.B. has received honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Otsuka, Pfizer, Roche, Sanofi and Servier and research funding from Bayer and Jazz Pharmaceuticals. D.S. reports that Kyverna Therapeutics provided research support to the institution in the context of an investigator-initiated trial (COMPARE trial), including financial support and product manufacturing. He has received speaker\u2019s honoraria from Kyverna Therapeutics and consulting fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, Lilly, Medac, Novartis, Pfizer and UCB. D.S. received speaker\u2019s honoraria from AbbVie, Alfasigma, Amgen, Bristol Myers Squibb, Janssen-Cilag, Lilly, Medac, Novartis and UCB not related to this study. G.K. reports speaker\u2019s honoraria and research funding from Kyverna Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}